Sugi Predict

Sugi Predict / Compounds / SCHEMBL13723749

SCHEMBL13723749

SCHEMBL13723749

COc1cc(N)ccc1N1CCC(C)(O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A1 P22736 2/20 0.49
▸ ALDH1A1 P00352 7/20 0.41
▸ ALDH1A3 P47895 1/20 0.41
▸ MAPT P10636 8/20 0.41
▸ GAA P10253 5/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ APOBEC3G Q9HC16 1/20 0.41
▸ DRD2 P14416 2/20 0.40
▸ THRB P10828 2/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.39
▸ PDE10A Q9Y233 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ RAD52 P43351 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15650361 0.92 NR4A1 (0.47) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL17076804 0.92 NR4A1 (0.47) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL14320542 0.92 NR4A1 (0.47) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL31353138 0.85 NR4A1 (0.49) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL13723942 0.85 NR4A1 (0.51) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL13724223 0.85 MAPT (0.43) NR4A1ALDH1A1MAPTGAAKDM4E
SCHEMBL15358685 0.84 NR4A1 (0.61) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL16440158 0.84 LMNA (0.42) ALDH1A1ALDH1A3MAPTGAAKMT2A
SCHEMBL10036161 0.84 NR4A1 (0.50) NR4A1ALDH1A1ALDH1A3MAPTGAA
SCHEMBL13725112 0.83 NR4A1 (0.44) NR4A1ALDH1A1ALDH1A3MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 — — US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 — — WO disclosed
US-20230203042-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS NANJING RUIJIE PHARMA CO., LTD. (CN) 2023-06-29 — — US disclosed
US-20230203042-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS NANJING RUIJIE PHARMA CO., LTD. (CN) 2023-06-29 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2699579-A1 PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 — — EP disclosed
EP-2699572-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 — — EP disclosed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 — — CN disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
WO-2012143144-A1 PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK NR4A1 3962/4885ALDH1A1 4333/4885ALDH1A3 3749/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK NR4A1 3992/4885ALDH1A1 3674/4885ALDH1A3 3122/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK NR4A1 3962/4885ALDH1A1 4333/4885ALDH1A3 3749/4885
US-20230203042-A1 COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS SYK, BTK, LCK NR4A1 3242/4885ALDH1A1 2839/4885ALDH1A3 4386/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK NR4A1 3962/4885ALDH1A1 4333/4885ALDH1A3 3749/4885
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR NR4A1 1561/4885ALDH1A1 1694/4885ALDH1A3 2137/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK NR4A1 4077/4885ALDH1A1 4184/4885ALDH1A3 3624/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK NR4A1 4077/4885ALDH1A1 4184/4885ALDH1A3 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.